Introduction:

Heberprot-P® is a novel and unique medication, prescribed for patients with diabetic foot ulcer. It is based on recombinant human growth factor that induces the growth of useful granulation tissue. The properties as oxygenating, antioxidant, immunomodulator, regenerator, anti-inflammatory and germicide of ozone therapy are used for the disinfection of wounds since the First World War.

Objective:

To determine the evolution of diabetic foot ulcers with the mixed treatment of Heberprot-P® and ozone therapy.

Methods:

A retrospective and descriptive study was conducted in all patients admitted to the National Institute of Angiology and Vascular Surgery (INACV) with the diagnosis of Diabetes Mellitus and diabetic foot ulcer who received mixed treatment of Heberprot-P® and ozone therapy. The study period ranged from January 2016 to January 2017. The studied variables were: sex, age, type of diabetes, hospital stay, need to be reoperated, granulation time and response to the treatment.

Results:

It was found that the highest percentage of patients who used the mixed treatment of Heberprot-P® and ozone therapy had a good response to treatment (60.5 %) and a granulation time between 2 and 4 weeks (55.6 %); and a hospital stay from 11 to 21 days.

Conclusions:

Patients with the mixed treatment of Heberprot-P® and ozone therapy have a very favorable response.

        · resumen en Español     · texto en Español     · Español ( pdf )